Who founded Synthego?

Synthego was founded by Paul John Dabrowski, Michael Jakub Dabrowski in 2012.

Who are Synthego's investors?

Synthego's investors include AAF Management Ltd., AME Cloud Ventures, Declaration Partners, Founders Fund, Khosla Ventures, Menlo Ventures, Open Field Capital, Perot Jain and 10 more.

How much funding has Synthego raised?

Synthego has disclosed $247M raised across 3 of its 6 known rounds.

Where is Synthego headquartered?

Synthego is headquartered in Redwood City, US.

Synthego

Redwood City, US · Founded 2012 · Delaware corporation · 176 employees on LinkedIn · 24 known investors

Find your way into Synthego

8 people in our graph share verified history with the Synthego team — schools, employers, funds. One of them is your warm intro.

Rebecca Nugentunlockedknows Craig Christianson · together at Synthego

×7knows the team · via Synthego

Synthego develops CRISPR gene-editing and molecular diagnostics products, including custom CRISPR editors in mRNA or protein formats, base editors, and cell-free protein and RNA production systems. It serves researchers and cell and gene therapy developers in the biotechnology industry.

Biotech Deep Tech Healthtech Medical Devices

Founders & leadership

Synthego was founded in 2012 by Paul John Dabrowski and Michael Jakub Dabrowski.

Paul John DabrowskiCo-founder

Michael Jakub DabrowskiCo-founder

Craig Christianson CEOChristianson spent over a decade at Promega Corporation, where he served as general counsel, general manager for North America, vice president of commercial operations, and a member of the board of directors. He later worked as an executive advisor at Water Street Healthcare Partners, co-founded MezLight, and was a co-owner of vcpi.

Board

Drew Oetting Board directorFounding partner of 8VC

Scott Nolan Board directorPartner at Founders Fund

Investors · 24

AAF Management Ltd.listed by AAF Management Ltd.Washington

How we know: AAF Management Ltd.'s portfolio page · the VCSheet dataset · Not right? Tell us

AME Cloud Ventureslisted by AME Cloud VenturesPalo Alto · $1M – $10M

How we know: AME Cloud Ventures's portfolio page · funding news · Not right? Tell us

Declaration Partnerslisted by Declaration PartnersBethesda

How we know: Declaration Partners's portfolio page · funding news · synthego.com · Not right? Tell us

Founders Fundlisted by Founders FundSan Francisco · $500K – $5Mvia Scott Nolan · board

How we know: Founders Fund's portfolio page · board seat on SEC Form D · funding news · Not right? Tell us

Khosla Ventureslisted by Khosla VenturesMenlo Park · $5K – $50M

How we know: Khosla Ventures's portfolio page · Not right? Tell us

Menlo Ventureslisted by Menlo VenturesSan Francisco · $1M – $20M

How we know: Menlo Ventures's portfolio page · a partner's Signal profile · funding news · Not right? Tell us

Open Field Capitallisted by Open Field CapitalNew York

Perot Jainlisted by Perot JainDallas · $500K

How we know: Perot Jain's portfolio page · Not right? Tell us

SoftBank Vision Fundlisted by SoftBank Vision FundLondon

WI Harper Grouplisted by WI Harper GroupSan Francisco · $5M – $15M

How we know: WI Harper Group's portfolio page · Not right? Tell us

Wormhole Capitallisted by Wormhole Capital

How we know: Wormhole Capital's portfolio page · Not right? Tell us

8VCreportedAustin · $100K – $50M

How we know: funding news · finance.yahoo.com · the VCSheet dataset · Not right? Tell us

Formation GroupreportedLos Altos

How we know: a partner's Signal profile · Not right? Tell us

GigafundreportedAustin · $1M – $5M

How we know: synthego.com · Not right? Tell us

Intel CapitalreportedSanta Clara · $1M – $20M

How we know: funding news · Not right? Tell us

OS FundreportedPark Ridge · $1M – $2M

How we know: funding news · the VCSheet dataset · Not right? Tell us

RA CapitalreportedBoston

How we know: funding news · synthego.com · Not right? Tell us

Wellington ManagementreportedBoston · $5M – $50M

How we know: hrnxt.com · Not right? Tell us

Also in the syndicate · 6

Chimera Abu DhabiLaurion Capital ManagementLogos CapitalMoore Strategic VenturesPerceptive AdvisorsleadSoftBank Vision Fund 2

Funding

SEC filings, press & company announcements

$247M disclosed across 3 of 6 rounds · 2016–2025

Undisclosed amountSeries EFeb 2022
Perceptive Advisors (lead), Chimera Abu Dhabi, Declaration Partners, GigaFund, Laurion Capital Management, Logos Capital, Moore Strategic Ventures, RA Capital Management, SoftBank Vision Fund 2, Wellington Management
Source ↗
$100MSeries DAug 2020 · 2 sources
Wellington Management (lead)
Source ↗

▶$106.3MraisedOct 2018 · 29 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Drew OettingDirector
Scott NolanDirector
Michael Jakub DabrowskiExecutive Officer, Director
Forrest Baringer-JonesExecutive Officer
Paul John DabrowskiExecutive Officer, Director

Offering amount: $116.3M
Amount sold: $106.3M
First sale: Oct 2018
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$40.7MraisedJan 2017 · 22 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Paul John DabrowskiExecutive Officer, Director
Michael Jakub DabrowskiExecutive Officer, Director
Drew OettingDirector
Scott NolanDirector

Offering amount: $40.7M
Amount sold: $40.7M
First sale: Dec 2016
Incorporated: Corporation, Delaware, 2012
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Founder mafia

The Synthego mafia →

9 people who came through Synthego went on to found or lead other companies.

Drew OettingDirectorFounded 8Vc +1 Nick ConleyAdvisor/InvestorFounded EpiBiome +1 Scott NolanDirectorFounded General Matter Humberto EvansSoftware EngineerFounded CircuitLab Fabian GerlinghausChief Innovation OfficerFounded Cellares Omar KurdiVP OperationsFounded Cellares Kevin HoldenVP of ScienceFounded NV Therapeutics John TanChief Operating OfficerFounded Editco Brandon RiceDirector of Product, Functional GenomicsFounded Weave Bio

Competitors · 2

by search overlap

CRISPR878 shared keywordsCRISPR Therapeutics is a biotechnology company developing gene-based medicines using CRISPR/Cas9 gene-editing technology. It is led by a management team, board of directors, and scientific founders from the biotech and pharmaceutical industries.

Read on Scientific American755 shared keywordsScientific American is a media organization that publishes research and ideas across science, health, technology and society through multiple formats including print, web, video, and podcasts. Founded in 1845, it reaches over 20 million people monthly and maintains editorial independence while providing trustworthy science communication and commentary.

Companies competing with Synthego for the same Google search keywords, organic and paid, via search-intersection analysis.

In the news

Synthego Raises $200 Million to Accelerate the Field of CRISPR-Based Medicines from Early-Phase Research to the Clinicsynthego.com · Feb 2022

Synthego Raises $100 Million in Series D Financingsynthego.com · Aug 2020

Synthego raises $100 million for AI-driven gene editing - Synthegosynthego.com · Aug 2020

Frequently asked questions

What does Synthego do?: Synthego develops CRISPR gene-editing and molecular diagnostics products, including custom CRISPR editors in mRNA or protein formats, base editors, and cell-free protein and RNA production systems. It serves researchers and cell and gene therapy developers in the biotechnology industry.
Who founded Synthego?: Synthego was founded by Paul John Dabrowski, Michael Jakub Dabrowski in 2012.
Who are Synthego's investors?: Synthego's investors include AAF Management Ltd., AME Cloud Ventures, Declaration Partners, Founders Fund, Khosla Ventures, Menlo Ventures, Open Field Capital, Perot Jain and 10 more.
How much funding has Synthego raised?: Synthego has disclosed $247M raised across 3 of its 6 known rounds.
Where is Synthego headquartered?: Synthego is headquartered in Redwood City, US.